Compass Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • News
  • Investors
  • Contact

News

Press releases

September 15, 2020
Compass Therapeutics, Inc. Provides Corporate Update
August 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models
June 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement
March 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
February 28, 2020
Compass Therapeutics to Present at the 40th Cowen Health Care Conference
January 6, 2020
Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
  • © 2021 Compass Therapeutics, Inc.
  • Terms & Conditions
  • Privacy Policy
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • News
  • Contact
  • Investors